MAZE files Form 144 to sell 46,892 shares

MAZE submitted a Form 144 notice indicating a proposed sale of 46,892 common shares scheduled on 07/01/2026.

Rhea-AI Filing Summary

MAZE submitted a Form 144 notice indicating a proposed sale of 46,892 common shares scheduled on 07/01/2026. The filing lists an exercise of stock options as the transfer method and shows cash proceeds treatment. The record includes two 10b5-1 sales by Harold Bernstein totaling 29,853 shares on 05/14/2026 and 06/01/2026, with reported proceeds of $393,354.00 and $381,113.13 respectively.

Insights

Securities Compliance Attorney

Form 144 lists a planned 46,892-share sale tied to option exercise.

The notice records a proposed sale date of 07/01/2026 and describes the method as an exercise of stock options with cash proceeds. Two prior dispositions under a 10b5-1 plan by Harold Bernstein are shown: 05/14/2026 (15,000 shares) and 06/01/2026 (14,853 shares).

Timing and transfer mechanics are explicit in the excerpt; the filing does not state whether the sales are brokered or the identity of purchasing parties. Subsequent SEC filings or broker confirmations would show execution details.

Corporate Governance Analyst

This is a routine officer/affiliate disposal notice rather than an operational disclosure.

The record ties the 46,892-share proposed sale to option exercise and labels the transaction "Issuer" with cash proceeds. The presence of recent 10b5-1 sales suggests pre-arranged dispositions rather than ad-hoc market trades.

Cash‑flow recipients and any beneficial‑ownership effects are not detailed in the excerpt; subsequent public filings may provide post-transaction holdings.

Key Figures

Proposed sale: 46,892 shares Aggregate offering price: $1,399,257.28 Prior 10b5-1 sale: 15,000 shares +2 more

5 metrics

Proposed sale 46,892 shares Proposed sale date <date>07/01/2026</date>

Aggregate offering price $1,399,257.28 Amount shown in the filing excerpt

Prior 10b5-1 sale 15,000 shares <date>05/14/2026</date> proceeds <b>$393,354.00</b>

Prior 10b5-1 sale 14,853 shares <date>06/01/2026</date> proceeds <b>$381,113.13</b>

Exchange listed NASDAQ Listing venue shown in the excerpt

Key Terms

Form 144, 10b5-1, Exercise of Stock Options, Issuer

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

10b5-1 regulatory

"10b5-1 Sales for HAROLD BERNSTEIN"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 07/01/2026 | Exercise of Stock Options"

Issuer regulatory

"Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does MAZE's Form 144 disclose about the planned sale?

The Form 144 discloses a proposed sale of 46,892 common shares tied to an exercise of stock options with a proposed date of 07/01/2026. The filing lists cash as the proceeds treatment for that transfer.

Who carried out recent sales reported in the filing for MAZE?

The filing shows two 10b5-1 sales executed by Harold Bernstein: 15,000 shares on 05/14/2026 and 14,853 shares on 06/01/2026, with reported proceeds of $393,354.00 and $381,113.13 respectively.

Does the Form 144 state who will receive the proceeds from the sale?

The excerpt identifies the transfer method as an exercise of stock options and labels the transaction type as Issuer with Cash treatment. It does not name the cash recipient beyond that label in the provided text.

Are the recent trades in the filing part of a pre-arranged plan?

Yes. The two prior dispositions by Harold Bernstein are described as 10b5-1 sales, indicating they were executed under a pre-arranged trading plan according to the language shown in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 05:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002050172
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 Oyster Point Blvd Suite 300 South San Francisco CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	HAROLD BERNSTEIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	46892	1399257.28	55345261	07/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2026	Exercise of Stock Options	Issuer			46892	07/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	06/01/2026	14853	381113.13
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	05/14/2026	15000	393354.00

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	07/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Harold Bernstein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)